Al Sandrock, Biogen R&D chief (Biogen via YouTube)

Bio­gen has a shaky end to H1 with a $542M write-off adding to its woes — but an­a­lysts see big rev­enue ahead for Aduhelm

All eyes at Bio­gen’s Q2 earn­ings call Thurs­day were on Aduhelm, but in­vestors al­so got a glimpse of what Bio­gen would have faced had the FDA not opt­ed to ap­prove their con­tro­ver­sial Alzheimer’s drug.

That glimpse, re­veal­ing a com­bi­na­tion of de­clin­ing sales, grow­ing com­pe­ti­tion and failed med­i­cines, un­der­scores the stakes of the big biotech’s Aduhelm ef­forts, as ex­ecs punch back at the crit­i­cism they’ve en­gen­dered in the po­lit­i­cal and med­ical world and vig­or­ous­ly push­es its sales staff to roll out the drug as fast as pos­si­ble.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.